$1.32
+0.02 (+1.54%)
Open$1.31
Previous Close$1.30
Day High$1.33
Day Low$1.26
52W High$2.35
52W Low$0.77
Volume—
Avg Volume162.4K
Market Cap20.68M
P/E Ratio—
EPS$-0.72
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,368.2% upside
Current
$1.32
$1.32
Target
$32.58
$32.58
$17.80
$32.58 avg
$40.39
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 354.8K | 2.19M | 1.96M |
| Net Income | -12,427,865 | -647,190 | -493,473 |
| Profit Margin | -3,509.7% | -29.6% | -25.2% |
| EBITDA | -13,947,339 | -712,204 | -583,546 |
| Free Cash Flow | — | -781,686 | -525,232 |
| Rev Growth | — | +18.0% | +10.8% |
| Debt/Equity | 0.14 | 0.28 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.53 | -1.09% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $361.16 | +0.17% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.13 | -0.16% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $494.74 | -0.98% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $628.06 | -0.59% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $297.43 | +1.33% | 69.3 | 39.97B |